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The combination of irinotecan plus 5-ﬂuorouracil and folinic acid has clinical and survival beneﬁts over 5-ﬂuorouracil and folinic
acid alone in the setting of ﬁrst line treatment of metastatic colorectal cancer. The aim of this cost-effectiveness analysis was to
compare the economic implications, from a UK health commissioner perspective, of the two treatment arms (de Gramont
regimen) in this setting. Resource utilisation data collected prospectively during the study were used as a basis for estimating
cumulative drug dosage, chemotherapy admistration, and treatment of complications during ﬁrst line therapy. Resource
utilisation associated with further chemotherapy in patients who had progressed during the study was derived from a
retrospective case note review. Drug acquisition costs were derived from the British National Formulary (September, 2001)
and unit costs for clinical consultation and services were taken from the latest relevant cost database. Cumulative costs per
patient associated with further chemotherapy were lower in the irinotecan plus 5-ﬂuorouracil and folinic acid treatment arm.
Based on incremental costs per life-year gained of £14794, the combination of irinotecan plus 5-ﬂuorouracil and folinic acid
can be considered cost-effective by commonly accepted criteria compared with 5-ﬂuorouracil and folinic acid alone. Thus,
clinical and economic data demonstrate that irinotecan, either in combination with irinotecan plus 5-ﬂuorouracil and folinic
acid in the ﬁrst line setting or as monotherapy in the second line setting, has a major role in the management of metastatic
colorectal cancer.
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With changes in population demographics, healthcare expenditure
is subject to continual review and ﬁnancial constraint. Clinicians
are increasingly being asked to consider both the clinical and
economic implications of new treatments and whether they repre-
sent value for money compared with currently available options.
Irinotecan (Campto
1, Aventis Pharma) is now widely accepted
in the USA and Europe as an acceptable second line therapy for
metastatic colorectal cancer based on clinical and economic consid-
erations (Rougier et al, 1998; Iveson et al, 1999). Recent data
(Douillard et al, 2000) have shown that irinotecan, in combination
with 5-ﬂuorouracil and folinic acid (5-FU/FA) provides a survival
advantage over 5-FU/FA alone, and this indication for ﬁrst line
treatment in metastatic colorectal cancer is reﬂected in the product
licence. The implication of these clinical data have prompted the
need for further pharmacoeconomic evaluation in this clinical
setting.
Colorectal cancer is the second most common cause of cancer
death in the UK and Western developed nations, representing
about 12% of all cancer deaths (Schmoll, 1994; Van Triest et al,
1995). Annually in the UK, there are over 27000 new cases of
colorectal cancer and over 18000 deaths due to metastatic disease
(Cancer Research Campaign, 1995). In the absence of treatment,
median survival from ﬁrst diagnosis of metastatic colorectal cancer
is short (typically 6–9 months) and quality of life is increasingly
compromised by both physical and psychological symptoms asso-
ciated with progression of disease (Seymour et al, 1997).
In the UK, palliative chemotherapy is offered to an increasing
number of patients with metastatic colorectal disease. At present
5-FU, usually modulated by FA, is regarded as standard ﬁrst line
therapy for metastatic colorectal cancer, with median survival time
of about 10–12 months (The Advanced Colorectal Cancer Meta-
analysis Project, 1992). Although there is no consensus of a ‘gold
standard’ schedule for these drugs, the de Gramont regimen (de
Gramont et al, 1997) is most commonly used in the UK (Seymour
et al, 1997). Additionally, in the absence of clear evidence of the
best therapeutic option in this setting, other factors such as conve-
nience, cost and quality of life inﬂuence clinical practice (Seymour
et al, 1997).
Irinotecan is a novel chemotherapeutic agent that acts to inacti-
vate DNA topoisomerase 1 and inhibit cell division (Shimada et al,
1994). There is no evidence of any cross-resistance with 5-FU
(Creemers et al, 1994). In the second line setting for metastatic
colorectal cancer, irinotecan has been shown to signiﬁcantly
improve survival compared with best supportive care alone
(Cunningham et al, 1998) or 5-FU with or without FA (Rougier
et al, 1998). In the ﬁrst line setting for metastatic disease, Phase
II studies in chemotherpy-naı ¨ve patients have shown promising
activity, with response rates ranging from 19–32% when adminis-
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et al, 1997). These preliminary data were conﬁrmed by a multicen-
tre, randomised, controlled, open-label study (Douillard et al,
2000) (see below), and resulted in the combination or irinotecan
with 5-FU/FA being licensed as a ﬁrst line therapy for metastatic
colorectal cancer.
Douillard et al (2000) compared treatment with the combina-
tion of irinotecan+5-FU/FA with 5-FU/FA alone in patients with
metastatic colorectal cancer; 385 patients received at least one cycle
of treatment; 199 patients received the combination of irinote-
can+5-FU/FA (treatment arm A) and 186 patients received 5-FU/
FA alone (treatment arm B) (see Table 1 for treatment regimens)
until the occurrence of disease progression, unacceptable toxicity
or withdrawal of consent. In a separate follow-up study in French
and UK centres, 62 patients who progressed during the study were
followed for up to 3 years until death or trial cut-off date (median
(range): 14.7 (11.5–21.1) months).
The aim of this study was to compare the economic implications,
from a UK health commissioner perspective, of differences in clin-
ical beneﬁt (response and time to progression) and survival between
the combination of irinotecan+5-FU/FA and 5-FU/FA alone as ﬁrst
line therapy for metastatic colorectal cancer. The analysis is based
on clinical and resource utilisation data collected prospectively as
part of the study (Douillard et al, 2000), as well as data relating
to further chemotherapy in patients with disease progression during
the study which were collected via a retrospective case note review.
Costs associated with drug acquisition, treatment delivery, disease
complications, and the use of second line chemotherapy were
included. Indirect costs, although important, have not been
included, as the data have been analysed from the viewpoint of
commissioners in the National Health Service (NHS).
MATERIALS AND METHODS
Clinical and resource utilisation data used for economic assess-
ments in this study are described below. These data provide the
basis for calculating the direct costs associated with each treatment
arm and for carrying out an economic evaluation comparing the
treatment arms with respect to their outcomes and associated costs.
Only data relating to patients who received the de Gramont regi-
men were included in the costs analysis (the AIO regimen is not
used in the UK) (Seymour et al, 1997), although overall survival
was based on all patient data (see Douillard et al, 2000). The
control arm (5-FU/FA) was valid from a UK perspective as this
regimen is most commonly used in the UK (Seymour et al, 1997).
All resource utilisation data were collected thoroughly by
prospective completion of Case Report Forms in the main trial
(Douillard et al, 2000) and retrospective collation of data in the
follow-up study. Both the clinical endpoints and conclusions drawn
from the subset for resource utilisation are valid due to the meth-
ods used for collection of data.
Clinical data
Patient characteristics of the two treatment arms of the study have
been previously summarised and reported (see Douillard et al,
2000). Treatment with the combination of irinotecan+5-FU/FA
was signiﬁcantly superior to 5-FU/FA alone with respect to
response rate (41 vs 23%, P50.001) in the evaluable patient popu-
lation, and was signiﬁcantly superior to 5-FU/FA alone with respect
to median time to disease progression (6.7 months vs 4.4 months,
P50.001) and median overall survival (16.8 months vs 14.0
months, P50.028) in the intent-to-treat patient population. The
median survival gain of the combination of irinotecan and 5-FU/
FA over 5-FU/FA alone (2.8 months or 0.23 life-years saved) was
achieved despite the fact that, of patients who received 5-FU/FA
alone, 58.3% received further chemotherapy and 31% were subse-
quently treated with a regimen containing irinotecan. Life-years
saved was a major efﬁcacy parameter used in the most-effectiveness
analysis.
Resource utilisation data
In estimating the economic impact of irinotecan in combination
with 5-FU/FA as ﬁrst line treatment for metastatic colorectal cancer
within the UK, it is insufﬁcient to examine only the drug acquisi-
tion costs. Hospitalisation (inpatient and outpatient settings) for
administration of treatment, nursing time and equipment use must
also be considered. In addition, costs associated with the toxicity of
treatment, most commonly diarrhoea and neutropenia, and
complications of the disease need to be examined. These later costs
can be broadly categorised as hospitalisation costs (other than for
routine administration of chemotherapy), consultation costs and
costs for clinical and diagnostic services. At each assessment in
the study, any hospital admission since the last visit was recorded,
together with the reason for admission, type of ward and length of
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Table 1 Details of treatment regimens used in the study of combination irinotecan+5-ﬂuorouracil/folinic acid (FU/FA) therapy versus 5-FU/FA therapy
alone
Treatment regimens
TREATMENT ARM A: Combination irinotecan and 5-FU/FA therapy (n=199)
EITHER
(n=145)Irinotecan+de Gramont
a regimen every 2 weeks. Irinotecan, 180 mg m
72 as a 90-minute intravenous (i.v.) infusion+folinic acid 200 mg m
72 i.v. over 2 h
followed by 5-FU 400 mg m
72 as an i.v. bolus then 5-FU 600 mg m
72 as a continuous i.v. infusion over 22 h day
71 on the ﬁrst 2 days of every 2-week
period.
1 cycle=3 infusions (6 weeks).
OR
(n=54) Irinotecan+weekly AIO
b regimen. Irinotecan, 80 mg m
72 as a 90-min i.v. infusion+5-FU 2300 mg m
72 per day i.v. over 24 h with folinic acid 500 mg m
72 i.v.
per day every week for 6 weeks, with 2-week rests between cycles.
1 cycle=6 infusions (7 weeks)
TREATMENT ARM B: 5-FU/FA alone (n=186)
EITHER
(n=143)de Gramont regimen every 2 weeks (see above)
a
1 cycle=3 infusions (6 weeks).
OR
(n=43) Weekly AIO regimen (see above)
b
1 cycle=6 infusions (7 weeks)
ade Gramont et al (1997).
bWeh et al (1994). As described in the trial paper (Douillard et al, 2000).
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well as inpatient and outpatient consultations with clinical person-
nel, were also documented. These data were recorded prospectively
during the study as an integral part of the Case Report Form
(CRF) and are presented as average ﬁgures for the irinotecan+5-
FU/FA treatment arm and the 5-FU/FA treatment arm.
Consideration of resource utilisation associated with further
chemotherapy following disease progression was essential in order
to present a balanced representation of the costs of treating
patients in the ﬁrst line setting. Over the trial and follow-up peri-
od, 39.4% of patients randomised to treatment with the
combination of irinotecan+5-FU/FA and 58.3% of patients rando-
mised to treatment with 5-FU/FA alone failed ﬁrst line therapy, i.e.,
progressed during the study and received further chemotherapy. In
most patients, these data relate to second line therapy, although it
is recognised that a small proportion may also relate to third line
therapy. Data relating to resource utilisation associated with
progression and second line therapy were collected via a retrospec-
tive case note review.
Drug acquisition costs during the study
All costs of changes were collected until progression or end of this
study. The cumulative dose per patient (mg) was derived from the
trial data (Douillard et al, 2000) using a mean body surface area of
1.8 m
2 collected in the trial. The median treatment duration was
shorter in the de Gramont 5-FU/FA treatment arm than in the
irinotecan+5-FU/FA combination treatment arm: 18.0 vs 24.6
weeks, respectively) (Douillard et al, 2000). Correspondingly, the
calculated cumulative number of infusions per patient given over
the study period was lower with 5-FU/FA than with the combina-
tion treatment (9.66 vs 12.08 infusions, respectively) (Tables 1 and
2). It is useful to note at this point that the higher treatment dura-
tion with irnotecan+5-FU/FA combination arm is reﬂective of the
safety of the regimen. Thus whilst more cycles may appear to
constitute higher costs, these need to be offset against the gains
provied in terms of increased survival.
Cumulative drug costs per patient were based on costs given in the
British National Formulary (BNF; September 2001) with allowance
for wastage. Where there was more than one option for the same
product, the lowest cost alternative was used for speciﬁc vial sizes.
Drug costs were calcualted by estimating the number of vials needed
to provide the required dose for each infusion and then multiplying
by the mean number of infusions per patient of each treatment.
Treatment administration costs during the study
As administration of the study treatment was deﬁned in the proto-
col, data relating to treatment delivery were not collected on the
CRF. Both treatment arms required insertion of a tunnelled central
line catheter by a doctor as well as the use of an infusional device.
Prospective data collection provided an estimate of the proportion
of inpatient hospitalisations and day hospital attendances required
per infusion in each treatment arm (see Table 3).
Hospitalisations were costed on the basis of 1997/98 extra-
contractual referral tariffs (i.e., tariffs negotiated between a hospital
and a local authority other than that responsible for the hospital)
collected from 12 NHS Trusts in the UK (Qost database). General
medicine and surgery ward tariffs were divided by the ofﬁcial aver-
age length of stay published by the Department of Health (1993/
94) (Department of Health Government Statistical Service, 1993)
in order to obtain a ‘per diem’ cost. The tariffs covered all types
of inpatient resources consumed.
Costs associated with complications of treatment and
disease during the study
All unplanned hospitalisations were recorded prospectively on the
Case Report Form. Hospital admissions due to complications
included those associated with adverse events resulting from
administration of chemotherapy and those resulting from disease
complications. Data for hospitalisation due to planned chemother-
apy administration were excluded. However, if hospitalisation for
chemotherapy administration was prolonged because of toxicity,
the hospital stay was retained in the calculation. Outpatient visits
were also categorised by the type of consultation. Other resource
items recorded on the CRFs related to the number of nurse visits
and radiotherapy (Table 4).
Unit costs for hospitalisation, specialist consultations and diag-
nostic costs were derived from the Qost database (1997/98) as
previously described. The consultation tariff included the costs of
procedures performed during the attendance. As diagnostic tests
were usually performed at hospital, outpatient Trust tariffs were
used in the costing of these services. Health professional, nurse
and GP consultations were costed on the basis of Personal Social
Services Research Unit (PSSRU) handbook (Netten and Dennett,
1998). As nurse and health professionals costs were given in hours,
it was assumed that each consultation would be of 0.5 h duration.
Overall cumualtive costs per patient associated with complica-
tions in each treatment arm were calculated using estimates of
the cumulative number of hospitalisations, consultations, and clin-
ical and diagnostic services required per treatment arm derived
from the trial data.
Cost associated with further chemotherapy
Data relating to resource utilisation associated with progression
and further chemotherapy were derived from a retrospective case
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Table 2 Cumulative drug acquisition costs per patient* during study
Irinotecan+5-FU/FA 5-FU/FA
Irinotecan 5-FU FA 5-FU FA
Cumulative dose (mg)
a 3914 21 744 4349 17 388 3478
No. of infusions
b 12.08 12.08 12.08 9.66 9.66
Dose/infusion (mg) 324 1800 360 1800 360
Infusion cost/drug (£)
c 419.00 13.97 126.07 13.97 126.07
Total cost/infusion (£)
a 419.00 140.04 140.04
Total drug cost (£)
c 6753.20 1352.79
*Only those patients who initially received de Gramont regimen (either alone or in combination with irino-
tecan).
aCalculated using a mean body surface area of 1.8 m
2, as determined from the trial (Douillard et al,
2000).
bRefer to Table 1, treatment regimens.
cCosts are derived from the BNF (March, 1999), based on the
use of 5 ml vials (£130 each) and 2 ml vials (£53 each) for irinotecan, 20 ml vials (£3.97 each) and 10 ml
vials (£2.06 each) for 5-FU, and 35 ml vials containing 10 mg ml
71 (£90.98 each) and 10 ml vials containing
3m gm l
71 (£35.09 each) for folinic acid (FA), with allowance for wastage.
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had progressed during the study. Costs associated with further
therapy following disease progression were categorised as either
drug costs (i.e., drug acquisition costs and costs associated with
treatment delivery) or disease progression costs (i.e., costs asso-
ciated with further hospitalisation and radiotherapy).
Information was collected on all treatment regimens used for
futher chemotherapy in each treatment arm. Wherever possible,
calculation of the number of infusions administered for each treat-
ment regimen was based on published sources (see Table 5).
Assumed cumulative costs per patient for each treatment regimen
were based on acquisition costs given in the British Natural Formu-
latory (BNF, March 1999), with allowance for wastage, and included
costs associated with treatment delivery. The actual cumulative drug
costs per patient associated with further chemotherapy were then
calculated by multiplying the total assumed cumulative drug costs
per patient of futher therapy by the proportion of patients in each
treatment arm who had received further therapy during follow-up
(i.e. 39.4% in the irinotecan+5-FU/FA combination treatment arm
and 58.3% in the 5-FU/FA treatment arm) (Douillard et al, 2000).
Retrospective data collection was used to estimate the total
cumulative hospitalisation and radiotherapy costs per patient asso-
ciated with disease progression. The actual cumulative costs per
patient associated with disease progression were then calculated
by multiplying by the proportion of patients in each treatment
arm who had progressed during the study.
Overall costs
In the setting of ﬁrst line therapy, the overall cumulative costs for
each treatment arm represented the total sum of costs associated
with ﬁrst line therapy and costs associated with disease progression,
including further chemotherapy. The incremental costs and
outcome with each treatment arm were compared. A cost effective-
ness ratio per life year gained (LYG) was calculated as the
difference in overall costs between the combination of irinote-
can+5-FU/FA and 5-FU/FA alone divided by the difference in
median survival between the combination regimen and 5-FU/FA
therapy alone (i.e., 2.8 months or 0.23 life-years saved; see Douil-
lard et al, 2000). A sensitivity analysis, based on UK data alone to
reﬂect the local situation, was also performed (Table 6).
RESULTS
Costs during the study
Cumulative costs during the study are summarised by treatment
arm in Tables 2, 3 and 4. As anticipated, cumulative drug acquisi-
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Table 3 Cumulative drug administration costs per patient* during study
Irinotecan+5-FU/FA 5-FU/FA
Unit Cumulative Cumulative
cost (£) Quantity
a cost (£) Quantity
a cost (£)
Hospitalisation costs
b
In-patient stay per infusion 195.19 0.5051 98.59 0.5161 100.74
Day hospital attendance per infusion 53.91 0.4949 26.68 0.4839 26.09
No. of infusions 12.08 1513.27 9.66 1225.13
Catheter and pump
Insertion of tunnelled central line catheter
c 250.00 1.00 250.00 1.00 250.00
Disposable pump
d 62.00 1.00 62.00 1.00 62.00
Total cumulative costs 1825.27 1537.13
*Only those patients who initially received de Gramont regimen (either alone or in combination with irinotecan).
aEstimated
from clinical trial data (Douillard et al, 2000).
bBased on Qost costs.
cIncludes the costs of doctor time, 0.5 day hospital stay
and chest X-ray.
dIncludes the costs of all disposables and pharmacist time.
Table 4 Cumulative costs per patient* associated with complications of disease and treatment
during study
Irinotecan+5-FU/FA 5-FU/FA
Unit Cumulative Total Cumulative Total
cost (£) quantity
a costs (£) quantity
a costs (£)
Hospital costs
b
Hospitalisation 195.19 5.19 1013.04 2.13 415.75
Outpatient consultations 58.00 3.26 189.08 2.56 148.48
Consultation category
c (visits) (visits)
Oncologist 128.33 0.36 46.20 0.16 20.53
Physiotherapist 50.00 0.07 3.50 0.08 4.00
Other specialist 61.69 0.54 33.31 0.33 20.36
General practitioner 9.00 0.58 5.22 0.48 4.32
Service costs
b (visits) (visits)
Nurse visits
d 12.00 1.71 20.52 1.52 18.24
Radiotherapy
e 122.67 1.38 169.28 4.2 515.21
Total cumulative costs 1480.15 1146.90
*Only those patients who initially received de Gramont regimen (either alone or in combination with irinote-
can).
aEstimated from clinical trial data (Douillard et al, 2000).
bUnit costs obtained from Qost.
cUnit costs for
consultation categories obtained from PSSRU (general practitioner) and Qost (other consultation categories).
dAssumed district nurse visit.
eAssumed outpatient attendance.
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tecan+5-FU/FA combination treatment arm than the 5-FU/FA
treatment arm (£6753 vs £1353, respectively) (Table 2). Cumulative
costs associated with treatment delivery (Table 3) and with drug
toxicity and disease complications (Table 4) were generally similar
in each treatment arm.
Costs during follow-up
However, the higher cumulative costs per patient associated with ﬁrst
line treament with irinotecan+5-FU/FA were offset by substantially
lower cumulative costs per patient during the trial and follow-up
period, probably attributable to reduced disease progression in the
combination treatment arm (39.4% vs 58.3% of patients, respec-
tively) (Douillard et al, 2000). Both cumulative drug costs per
patient (£2007 in the irinotecan+5-FU/FA arm vs £3601 in the 5-
FU/FA arm) (Table 5), and cumulative diseaase progression costs
per patient during follow-up (£1484 vs £2460, respectively) (Table
6) were up to 45% lower in the combination treatment arm.
Total costs
When cumulative costs per patient associated with ﬁrst line
(during study) and further (during follow-up) chemotherapy were
considered together, it is apparent that the overall cumulative costs
per patient in the irinotecan+5-FU/FA combination treatment arm
were higher than those associated with 5-FU/FA alone (difference
in costs, £3452) (Table 7).
However, treatment with the combination of irinotecan+5-FU/
FA in the ﬁrst line setting also resulted in a signiﬁcant gain in
median survival over 5-FU/FA alone (0.23 life-years (Douillard et
al, 2000)). Cost-effectiveness analysis of incremental costs and
survival relative to 5-FU, demonstrated that treatment with the
combination of irinotecan+5-FU/FA in the ﬁrst line setting resulted
in incremental costs per LYG of £14794. Sensitivity analyses based
on UK data alone showed that there was little change in incremen-
tal costs per LYG when rates were varied to reﬂect UK practice
(£16015).
DISCUSSION
Combination treatment with irinotecan+5-FU/FA is now licensed
as a ﬁrst line therapy for metastatic colorectal cancer. Compared
with 5-FU alone, the combination of irinotecan+5-FU/FA offers a
signiﬁcant survival advantage without detriment to quality of life
(Douillard et al, 2000).
However, the introduction of new treatments to hospital
formularies requires demonstration of cost as well as clinical
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Table 5 Cumulative overall drug costs per patient* associated with further chemotherapy**
during follow-up
Irinotecan+5-FU/FA 5-FU/FA
Per cent Total Per cent Total
Follow-up chemotherapy of patients costs (£) of patients costs (£)
Irinotecan 1.61 23.81
5-FU/FA (Mayo regimen) 1.61 –
5-FU/FA (de Gramont regimen)
a 4.84 3.18
5-FU/FA (Lokich regimen)
a 9.68 6.35
Irinotecan+5-FU/FA (de Gramont regimen)
a 19.36 12.70
Oxaliplatin
b 1.61 –
Oxaliplatin
b+Irinotecan
a – 7.94
Oxaliplatin
b+5-FU/FA
a (de Gramont regimen) 41.93 26.98
Mitomycin C
c 4.84 1.59
Mitomycin C+5-FU/FA
d 6.45 9.52
Raltitrexed 1.61 –
Chronotherapy
e 3.23 7.93
Assumed total cumulative costs
f 100.00 5093 100.00 6176
Per cent patients receiving second line therapy
g 39.4 2006.76 58.3 3600.7
*Only those patients who initially received de Gramont regimen (either alone or in combination with irinote-
can) during study. **Most of these data relate to second-line therapy, although it is recognised that a small
proportion of third-line therapy may be included. Treatment regimens as described in:
aIveson et al (1999).
bLevi et al (1993).
cHartmann et al (1998).
dRoss et al (1997).
eLe ￿vi et al (1997).
fCosts are derived from
the BNF (March, 1999).
gFrom trial data (Douillard et al, 2000).
Table 6 Cumulative overall costs per patients* associated with disease progression during follow-up
Irinotecan+5-FU/FA 5-FU/FA
Unit Cumulative Total Cumulative Total
cost (£) quantity
a costs (£) quantity
a costs (£)
Assumed costs
Hospital admissions
b 195.19 19.23 3753.50 21.47 4190.73
Radiotherapy
c 122.67 0.1129 13.85 0.2382 29.22
Total assumed costs 3767.35 4219.95
Per cent patients receiving second line therapy
d 39.40 1484.34 58.30 2460.23
*Only those patients who initially received de Gramont regimen (either alone or in combination with irinotecan) during
study.
aEstimated from follow-up clinical trial data.
bUnit costs obtained from Qost.
cAssumed outpatient attendance.
dFrom trial data (Douillard et al, 2000).
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relative to current best practice, speciﬁcally with respect to value
parameters such as survival gain. Deﬁning arbitrary ﬁnancial limits
based on such value parameters is difﬁcult, particularly as there is a
general paucity of guidelines on which to base judgements. Yet
choices are inevitable and necessary.
In the UK, there are no guidelines for using clinical and
economic evaluations, and no deﬁned limit at which the incremen-
tal costs and clinical beneﬁts of a treatment favour its introduction
into routine clinical practice. However, tentative limits can be
surmised from a recent Department of Health review of available
cost-effectiveness studies (Department of Health, 1994). These data
(Department of Health, 1994) suggest that incremental costs per
LYG of £15000–£20000 for a cancer treatment can be considered
reasonable, and hence the treatment may be viewed as cost-effec-
tive compared with currently accepted best practice. Based on
these considerations, treatment with irinotecan+5-FU/FA was asso-
ciated with only a modest increase in cost compared with 5-FU/FA
alone (as supported by sensitivity analyses involving only UK data),
which together with the signiﬁcant survival gain demonstrated for
the combination treatment (Douillard et al, 2000), justiﬁes its use
as a ﬁrst line therapy for metastatic colorectal cancer.
In conclusion, the results of the cost effectiveness analysis
presented in this study, together with clinical evidence (Douillard
et al, 2000), strongly support the use of irinotecan+5-FU/FA in
the setting of ﬁrst line therapy of metastatic colorectal cancer.
Moreover, clinical (Rougier et al, 1998) and economic (Iveson et
al, 1999) studies have conﬁrmed the superiority of irinotecan in
the setting of second line therapy. Thus, irinotecan, either alone
or in combination with 5-FU/FA, represents an important thera-
peutic advance in the management of metastatic colorectal cancer.
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Table 7 Comparison of overall cumulative costs per 100 patients and
cost-effectiveness per life year gained (LYG) with irinotecan+5-FU/FA
compared with 5-FU/FA alone (de Gramont regimen)*
Irinotecan+ 5-FU/FA
5-FU/FA (£) (£)
During study
a
Drug acquisition costs 6753.20 1352.79
Drug administration costs 1825.00 1537.00
Complication costs 1480.15 1146.90
During follow-up
b
Further chemotherapy costs 2006.76 3600.73
Disease progression costs 1484.34 2460.23
Total costs during study and follow-up 13550 10098
Difference in costs 3452
Difference in survival 0.23
c
Cost-effectiveness ratio/LYG
d 14794
*Only those patients who initially received de Gramont regimen (either alone or in
combination with irinotecan) during study.
aRefer to Tables 3, 4 and 5 for derivation.
Derived from clinical trial data (Douillard et al, 2000).
bRefer to Tables 6 and 7.
Derived from clinical trial follow-up data.
cFrom clinical trial data. Abbreviated actual
ﬁgure is 0.233333333 (Douillard et al, 2000).
dCost-effectiveness ratio per life years
gained (LYG) was deﬁned as:

total costI ÿ total cost5-FU
survivalI ÿ survival5-FU
where I=irinotecan+5-ﬂuorouracil/folinic acid therapy and 5-FU=5-ﬂuorouracil/folinic
acid therapy.
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